Friday, October 30, 2009
FRIDAY, Oct. 30 (HealthDay News) -- Endorectal magnetic resonance (MR) imaging may be useful in categorizing men with stage T1c prostate cancer for proper treatment management, according to research published in the November issue of Radiology.
Jingbo Zhang, M.D., of the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues analyzed data from 158 men with a diagnosis of clinical stage T1c prostate cancer who underwent endorectal MR imaging along with proton MR spectroscopic imaging before radical prostatectomy. All had whole-mount step-section pathology maps available for correlation of imaging and pathologic analysis.
At the surgical-pathologic analysis, the researchers found that 78 percent had stage pT2 organ-confined disease, 18 percent had stage pT3a with extracapsular extension, and 1 percent each had seminal vesicle and bladder neck invasion. The combined use of endorectal MR imaging and MR spectroscopic imaging showed 80 percent accuracy in the staging of these patients' disease, and moderate accuracy in predicting clinically non-important cancer.
"With the routine practice of PSA screening, stage T1c has become the most commonly diagnosed clinical stage of prostate cancer," the authors write. "In conclusion, clinical stage T1c prostate cancers are heterogeneous in pathologic stage and volume. Endorectal MR imaging can yield additional valuable diagnostic information about patients with these cancers."
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.